TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Dolutegravir in Pregnant HIV Mothers and Their Neonates

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Evidence of a personally signed and dated informed consent document indicating that the participant has been informed of all pertinent aspects of the study.~2. Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.~3. Women aged 18 years or older~4. Pregnant ( ≥28 weeks gestation by best available gestation estimation)~5. Untreated HIV infection in late pregnancy~Exclusion Criteria:~1. Received any antiretroviral drugs in previous 12 months~2. Ever received integrase inhibitors~3. Previous documented failure of an NNRTI-containing ART regimen, previous EFV-associated toxicity or other history of ARV use that would preclude randomisation based on investigator judgement~4. Serum haemoglobin \<8.0 g/dl~5. eGFR\<50 ml/min\*~6. Elevations in serum levels of alanine aminotransferase (ALT) \>5 times the upper limit of normal (ULN) or ALT \>3xULN and bilirubin \>2xULN (with \>35% direct bilirubin).~7. History or clinical suspicion of unstable liver disease (as defined by the presence of ascites, encephalopathy, coagulopathy, hyperbilirubinaemia, oesophageal or gastric varices or persistent jaundice).~8. Severe pre-eclampsia (e.g. HELLP), or other pregnancy related events such as renal or liver abnormalities (e.g. grade 2 or above proteinuria,, total bilirubin, ALT or AST)\* at the time of enrolment~9. Paternal objection for infant participation in DTG arm (where disclosure has taken - applies to Uganda site only~10. Medical, psychiatric or obstetric condition that might affect participation in the study based on investigator judgement~11. Receiving any of the following medications (current or within past 2 weeks): anti-epileptic drugs, TB therapy, or other drugs known to significantly interact with either DTG or EFV

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dolutegravir (Type: EXPERIMENTAL): Dolutegravir group (DTG+2 NRTIs) - to make best comparison with standard of care, these NRTIs should be those recommended by national policy.~Participants randomized to the study drug will be commenced on an antiretroviral regimen comprising DTG 50mg once daily in combination with 2 NRTIs
- Standard of Care (EFV + 2 NRTI backbone) (Type: ACTIVE_COMPARATOR): Participants randomized to receive standard of care will receive the currently used antiretroviral regimens in keeping with national policy (EFV + 2NRTIs at both study sites).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Adefovir Dipivoxil In Compensated Chronic Hepatitis B Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Have compensated chronic hepatitis B.~* Have not been treated with anti HBV agents with antiproliferative activity against. However, previous Interferon (IFN) therapy is permitted.~* Ability to read, understand, and sign the informed consent.~* Have a positive serum HBV-DNA \>= 1,000,000 copies/mL and ALT level 50-500 U/L~Exclusion criteria:~* Having or suspected of having liver cancer.~* Co-infected with Hepatitis C virus (HCV) or Human Immunodeficiency virus (HIV).~* Autoimmune hepatitis.~* Received any previous transplantation or having a plan for any transplantation.~* Existence of any serious complication, except hepatitis B.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Adefovir Dipivoxil (ADV) (Type: EXPERIMENTAL): None
- Lamivudine (LAM) (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A One-Year, Open-Label Study With Teduglutide for Subjects Who Completed Study CL0600-021

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* At completion of Study CL0600-021, subjects will be invited to participate in this trial if they meet the following criteria:~  1. Completion of the 24-month study, CL0600-021, regardless if fully weaned from PN/I.V. support~ 2. Signed and dated informed consent form (ICF) to participate before any study-related procedures of Study TED-C11-001 are performed~Exclusion Criteria:~* None

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Teduglutide (Type: EXPERIMENTAL): 0.05 mg/kg/day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Stimulant Abuser Groups to Engage in 12-Step

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* seeking outpatient treatment for stimulant abuse or dependence~* current diagnosis of stimulant abuse or dependence~* willing to participate in the protocol~Exclusion Criteria:~* not sufficiently medically or psychiatrically stable~* pending legal action that would inhibit their participation in the study~* in need of detoxification from opiates

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- STAGE-12 (Type: EXPERIMENTAL): STAGE-12 received 3 individual and 5 group 12-step facilitation sessions focusing on 12-step principles plus an intensive referral in which counselors linked participants to community-based 12-step volunteers. These sessions took the place of 3 individual and 5 group sessions in the standard intensive outpatient drug treatment program and were integrated into treatment as usual.
- Treatment as Usual (Type: ACTIVE_COMPARATOR): Treatment as usual received standard care provided in intensive outpatient drug treatment program without the STAGE-12 components.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Ziprasidone in Children and Adolescents With Bipolar I Disorder (Manic or Mixed)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* DSM-IV criteria for Bipolar I disorder (manic or mixed); age 10 - 17 years~Exclusion Criteria:~* Imminent risk of suicide or homicide, as judged by the site investigator; any history of serious or unstable medical illness, including risk for QT prolongation

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Ziprasidone oral capsules (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Healthcare Utilization and Outcomes of FinESS Treatment in the Office

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years or older~* Male or female subjects~* Diagnosis of rhinosinusitis (CT radiographic evidence and medical evaluation)~* Willing to comply with protocol requirements~* Able to provide consent~Exclusion Criteria:~* Hemophilia~* Cystic fibrosis~* Ciliary dysfunction~* Severe septal deviation causing obstruction of the ostiomeatal unit~* Pregnant females

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Balloon Dilation (Type: EXPERIMENTAL): Balloon dilation of the maxillary sinuses using the FinESS Sinus Treatment device.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of LDL Cholesterol in Patients Switched From 10 to 5 Milligrams of Zetia (Ezetimibe)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects receiving ezetimibe 10 mg~* Subjects who have demonstrated compliance with ezetimibe as evidenced by the following Proportions of Days Covered patterns (which represent a PDC of more than 75%):~  * 90 day prescriptions: Filled a ezetimibe prescription within the previous 4 months~ * 60 day prescriptions: Filled a ezetimibe prescription within the previous 2.5 months~ * 30 day prescriptions: Filled a ezetimibe prescription within the previous 1.5 months~* Patients willing and able to provide signed informed consent~Exclusion Criteria:~* Patients not receiving ezetimibe~* Patients receiving ezetimibe 5 milligrams~* Patients with a history of being titrated from ezetimibe 5 to 10 mg. Stroke,TIA, myocardial infarction, unstable angina, percutaneous coronary intervention, coronary artery bypass surgery, or major surgery within the 3 months~* Cancer undergoing active treatment~* Participation in any clinical study within the last 30 days~* Drug addiction or alcohol abuse within the past 6 months~* Patients unwilling or unable to provide informed consent~* Patients with poor compliance~* Women of childbearing potential

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ezetimibe 10 mg (Type: ACTIVE_COMPARATOR): A whole ezetimibe 10 mg tablet
- Ezetimibe 5 mg (Type: EXPERIMENTAL): Ezetimibe 5 mg, formulated by splitting a 10 mg ezetimibe tablet in half

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Of Anti-IGF-IR CP-751,871 In Patients With Solid Tumors

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Ewing's sarcoma family tumors~Exclusion Criteria:~* Concurrent treatment with any other anti tumor agents

- Gender: ALL
- Minimum Age: 9 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Tamsulosin and Solifenacin in Treatment of Ureteral Stent Symptoms

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Patient who will undergo unilateral ureteral stent fixation:~1. To relieve upper urinary tract obstruction caused by ureteric calculi~2. After ureteroscopic lithotripsy for ureteral calculi.~Exclusion Criteria:~1. Patients who had LUTS before stent fixation.~2. Ureteral stent fixation after open or laparoscopic surgery.~3. Bilateral ureteral stents.~4. Patients who developed complications related to the primary endoscopic procedure~5. Patients who developed stent related complications such as hematuria, acute pyelonephritis or stent displacement

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Group A (Type: PLACEBO_COMPARATOR): Patients in this group will receive placebo
- Group B (Type: ACTIVE_COMPARATOR): Patients in this group will receive Tamsulosin
- Group C (Type: ACTIVE_COMPARATOR): Patients in this group will receive Solifenacin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: HBOT Effect on Chronic Pain Syndrome With a History of Psychological Trauma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Females~* Age over 18~* Known fibromyalgia (chronic pain syndrome) for more than 1 year~Exclusion Criteria:~* Any past hyperbaric treatment prior to inclusion~* Patients with chest x-ray pathology incompatible with hyperbaric environment~* Patients with middle ear problems~* Patients, who cannot pump, equals middle ear pressure, effectively~* Patients who suffer from claustrophobia~* Inability or Refusing to sign the Informed Consent Form

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Combined HBOT/psychotherapy (Type: ACTIVE_COMPARATOR): combined concurrent intervention of HBOT and creative art psychotherapy.
- psychotherapy (Type: OTHER): single intervention with creative art psychotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Safety Study of Flu Vaccine in Immunodepression Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion criteria :~* informed consent signed~* Age between 18 to 64~* Patient suffering from chronic inflammatory bowel disease (Crohn's disease, ulcerative colitis, or indeterminate colitis)~* For patients receiving at least one immunosuppressive or anti-TNF therapy: treatment introduced for at least 3 months~* Patient willing to participate in the study throughout its duration and acceptance procedures related to the study (blood samples, self questionnaires, nasal swab and telephone follow-up)~Exclusion criteria :~* Patient treated by corticosteroid alone without immunosuppressive or anti-TNF~* For women, being pregnant or positive pregnancy test~* Known allergy to any component of the study vaccine or a history of hypersensitivity reaction to influenza vaccination~* Fever (at least 37.5°C measured orally) or acute infection in the week prior to vaccination~* Received influenza vaccination in the 6 months preceding enrollment~* Known history of progressive neuropathy or Guillain-Barre~* Known infection with HIV and/or HBV (Ag-HBs positive) and/or HCV~* Other causes of severe immune deficiency~* Cellular therapy, immunoglobulin infusions, of blood products or monoclonal antibodies (except anti-TNF) in the 3 months prior to vaccination~* Patient deprived of freedom by an administrative or court order~* Patient non affiliated to a health social security system

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- 2 (Type: EXPERIMENTAL): patients with IBD receiving immunosuppressants (TNF blockers excluded) (n=100)
- 3 (Type: EXPERIMENTAL): patients with IBD receiving immunosuppressants including TNF blockers (n=100)
- 1 (Type: EXPERIMENTAL): patients with IBD not receiving immunosuppressant (n=100)
- 4 (Type: ACTIVE_COMPARATOR): patients with IBD receiving immunosuppressants including TNF blockers (n=20)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Propolis Mouthwash on Gingivitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Gingival index \>1~* Periodontal pocket depth ≤ 3 mm~* Clinical attachment loss 0~* Provision of written informed consent~* Good systemic health.~Exclusion Criteria:~* Severe periodontal disease, as characterized by purulent exudates, generalized mobility, and/or severe recession~* Any condition that requires antibiotic premedication for the administration of a dental prophylaxis.~* Self-reported pregnancy, intent to become pregnant during the study, or breast-feeding.~* Any diseases or condition that could be expected to interfere with the safe completion of the study.~* History of antibiotic use in the previous 3 months.~* Individuals with orthodontic appliances or prosthetic appliances that would interfere with evaluation.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 30 Years
- Healthy Volunteers: t

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Subjects were asked to rinse 10 ml of mouthwash twice daily for 21 days.
- Propolis (Type: EXPERIMENTAL): Subjects were asked to rinse 10 ml of mouthwash twice daily for 21 days.
- Chlorhexidine (Type: ACTIVE_COMPARATOR): Subjects were asked to rinse 10 ml of mouthwash twice daily for 21 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Long-Duration Stimulant Treatment Study of ADHD in Young Children

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Parents/guardians and children must speak English and/or Spanish; parents/guardians must sign consent form; children must verbally assent.~2. Boys and girls from 4-5 years old (inclusive) at screening.~3. Children who meet the DSM-IV criteria for a primary diagnosis of ADHD (combined or hyperactive subtype), with symptoms present for at least 9 months.~4. Children who demonstrate adequate need for treatment due to ADHD symptom-severity and clinical impairment.~5. Children with IQ of at least 70 confirmed by valid IQ test.~6. Children who are in educational settings (pre-school, kindergarten, or elementary school program) with at least 8 same-age peers for at least two half days weekly.~7. Parents and children who can attend weekly study visits.~8. Children who are naïve to ADHD medications; received ADHD medications in the past but are not currently treated; or on ADHD medications but finding them inconvenient (due to short duration of action) or not very helpful~Exclusion Criteria:~1. Children and parents/guardians who do not understand or cannot follow necessary instructions; children and parents who are unwilling to comply with study procedures or cooperate with child psychiatrist.~2. Children taking excluded medications.~3. Children with history of intolerance to MPH/stimulant medications or no response to adequate stimulant trials.~4. Children with current adjustment disorder, autism, psychosis, bipolar disorder, significant suicidality, or other psychiatric disorders.~5. Children with history of physical, sexual, or emotional abuse, which lead to a significant impact on the clinical presentation and potentially some ADHD symptoms.~6. Children with screening abnormalities deemed clinically significant by child psychiatrist.

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 5 Years
- Healthy Volunteers: t

Study Arms:
- ADHD Treatment Group (Type: EXPERIMENTAL): Single-arm, open-label, once-daily-dosing of long-duration beaded MPH (B-MPH) at 10-30 mg (flexible titration) in 4-to-5 year old children with ADHD.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Subjects With Severe Hemophilia A

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male, ≥12 years of age with weight at least 40 kg~* Diagnosed with severe hemophilia A, defined as \<1 IU/dL (\<1%) endogenous Factor VIII)~* History of at least 150 documented prior exposure days to any Factor VIII product~* Platelet count ≥100,000 cells/μL~Exclusion Criteria:~* History of Factor VIII inhibitors~* Kidney and liver dysfunction~* Diagnosed with other coagulation disorder(s) in addition to hemophilia A~* Prior history of hypersensitivity or anaphylaxis associated with any FVIII or IV immunoglobulin administration

- Gender: MALE
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Individualized (Tailored) Prophylaxis (Type: EXPERIMENTAL): On rFVIIIFc Day 0, all participants underwent pharmacokinetic (PK) analysis with 50 IU/kg rFVIIIFc to estimate their PK parameters and guide the appropriate dose or interval of dosing. A subset of participants (Sequential PK subgroup) also had PK analyses performed with a single dose of 50 IU/kg Advate (Advate Day 0) within 8 weeks prior to rFVIIIFc Day 0. A \>= 96 hour washout was performed before the PK dose of Advate or rFVIIIFc was administered. Repeat PK profiling with a single dose of 50 IU/kg rFVIIIFc was conducted at Week 14 or after 12 to 24 weeks of prophylaxis with rFVIIIFc.~After PK assessments, all participants started twice weekly treatment with 25 IU/kg of rFVIIIFc via intravenous (IV) injection on Day 1 and 50 IU/kg on Day 4, followed by individualized dose and interval modification within the range of 25 to 65 IU/kg every 3 to 5 days, as determined by rFVIIIFc PK analysis, to maintain a trough level of 1% to 3% (or higher, as clinically indicated) FVIII activity.
- Weekly Prophylaxis (Type: EXPERIMENTAL): 65 IU/kg of rFVIIIFc via IV injection every 7 days
- Episodic (On-Demand) Dosing (Type: EXPERIMENTAL): 10 to 50 IU/kg rFVIIIFc via IV injection, as required to treat a bleeding episode

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete